Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety

Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and play an important role in the treatment of osteoporosis, metastatic bone disease, and Paget disease. However, nephrotoxicity has been reported with some bisphosphonates. Nitrogen-containing bisphosphonates directly inhi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Toxicology in vitro 2008-06, Vol.22 (4), p.899-909
Hauptverfasser:	Lühe, Anke, Künkele, Klaus-Peter, Haiker, Monika, Schad, Karen, Zihlmann, Christine, Bauss, Frieder, Suter, Laura, Pfister, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bisphosphonates Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - toxicity Cell Line Clodronate Clodronic Acid - toxicity Diphosphonates - administration & dosage Diphosphonates - toxicity Dose-Response Relationship, Drug Drug Evaluation, Preclinical Farnesyl diphosphate synthase Geranyltranstransferase - antagonists & inhibitors Geranyltranstransferase - metabolism Humans Ibandronate Imidazoles - administration & dosage Imidazoles - toxicity Inhibitory Concentration 50 Kidney Kidney - cytology Kidney - drug effects Kidney - enzymology Male Mevalonate pathway Nephrotoxicity Nitrogen-containing bisphosphonates Non-nitrogen containing bisphosphonates Pamidronate Rats Rats, Sprague-Dawley Renal RNA, Messenger - drug effects RNA, Messenger - metabolism Zoledronate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!